AUTHOR=Cui Rongrong , Yan Long , Kang Kaijiang , Yang Ming , Yu Ying , Mo Dapeng , Gao Feng , Wang Yongjun , Lou Xin , Miao Zhongrong , Ma Ning 

TITLE=Long-Term Outcome of Enterprise Stenting for Symptomatic ICAS in a High-Volume Stroke Center

JOURNAL=Frontiers in Neurology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.672662

DOI=10.3389/fneur.2021.672662

ISSN=1664-2295

ABSTRACT=<p><bold>Background and Purpose:</bold> The Enterprise stent has been used for treating intracranial atherosclerotic stenosis (ICAS), but its long-term outcome remains unclear. The purpose of this study was to evaluate the long-term clinical efficacy of the Enterprise stent used for patients with symptomatic ICAS due to hypoperfusion.</p><p><bold>Method:</bold> Patients with symptomatic ICAS due to hypoperfusion treated with the Enterprise stents from a high-volume stroke center were evaluated. The successful recanalization was defined as the Modified Thrombolysis In Cerebral Infarction (mTICI) ≥ 2b. The stroke and neurological death that occurred within 72 h after the procedure as well as long-term clinical and imaging outcomes were analyzed.</p><p><bold>Results:</bold> Overall, 130 patients with 130 ICAS treated with the Enterprise stent were included in our study. The successful recanalization rate was 100%. The mean pre- and postprocedural stenosis was 82.9 ± 8.9% vs. 15.1 ± 8.4%. Periprocedural complications occurred in 5 (3.8%) patients within 72 h after the procedure. Clinical follow-up data were available in 125 (96.2%) patients (median, 24 months) and any stroke or neurological death was encountered in 6 (4.8%) patients. Angiographic follow-up data was obtained from 118 (90.8%) patients (median, 13.5 months). In addition, 1-year in-stent restenosis (&gt;70%) was found in 17 (14.4%) patients, and among them, 4 (23.5%) patients were symptomatic.</p><p><bold>Conclusion:</bold> Deployment of Enterprise stent is safe for ICAS. The short-term and long-term outcomes were acceptable, but the efficacy of the Enterprise stent needs to be further evaluated in future studies.</p>